1. Centers for Disease Control and Prevention. About HIV. June 2022. https://www.cdc.gov/hiv/basics/whatishiv.html. (Accessed February 9, 2024).
2. Centers for Disease Control and Prevention. HIV: basic statistics. May 2023. https://www.cdc.gov/hiv/basics/statistics.html. (Accessed February 9, 2024).
3. Centers for Disease Control and Prevention. HIV in the United States by Region: HIV Diagnoses. October 2022. https://www.cdc.gov/hiv/statistics/overview/diagnoses.html. (Accessed February 9, 2024).
4. Centers for Disease Control and Prevention. Ways HIV is Not Transmitted. April 2021. https://www.cdc.gov/hiv/basics/hiv-transmission/not-transmitted.html. (Accessed February 9, 2024).
5. Centers for Disease Control and Prevention. HIV risk behaviors. November 2019. https://www.cdc.gov/hiv/risk/estimates/riskbehaviors.html. (Accessed February 9, 2024).
6. Centers for Disease Control and Prevention. Ways HIV Can Be Transmitted. March 2022. https://www.cdc.gov/hiv/basics/hiv-transmission/ways-people-get-hiv.html. (Accessed February 9, 2024).
7. Centers for Disease Control and Prevention. HIV and Injection Drug Use. April 2021. https://www.cdc.gov/hiv/basics/hiv-transmission/injection-drug-use.html. (Accessed February 9, 2024).
8. Ciesielski CA, Bell DM, Marianos DW. Transmission of HIV from infected health-care workers to patients. AIDS. 1991;5(Suppl 2):S93-7.
9. Lot F, Seguier JC, Fegueux S, et al. Probable transmission of HIV from an orthopedic surgeon to a patient in France. Ann Intern Med. 1999;130:1-6.
10. Ishimaru T, Wada K, Smith DR. A consensus for occupational health management of healthcare workers infected with human immunodeficiency virus, hepatitis B virus, and / or hepatitis C virus. J Occup Health. 2017;59:304-8.
11. Centers for Disease Control and Prevention. HIV and Occupational Exposure. September 2019. https://www.cdc.gov/hiv/workplace/healthcareworkers.html. (Accessed February 9, 2024).
12. Centers for Disease Control and Prevention. HIV testing. June 2022. https://www.cdc.gov/hiv/testing/index.html. (Accessed February 9, 2024).
13. Centers for Disease Control and Prevention. Understanding the HIV Window Period. June 2022. https://www.cdc.gov/hiv/basics/hiv-testing/hiv-window-period.html. (Accessed February 9, 2024).
14. Centers for Disease Control and Prevention. State Laws that address High-Impact HIV Prevention Efforts. March 2022. https://www.cdc.gov/hiv/policies/law/states/index.html. (Accessed February 9, 2024).
15. The Florida Legislature. The 2023 Florida statutes. Chapter 381.004: HIV testing. http://www.leg.state.fl.us/Statutes/index.cfm?App_mode=Display_Statute&URL=0300-0399/0381/Sections/0381.004.html. (Accessed February 9, 2024).
16. The Florida Senate. 2023 Florida Statutes. Chapter 384 (section 25): sexually transmissible diseases – Reporting required. https://m.flsenate.gov/Statutes/384.25. (Accessed February 9, 2024).
17. Centers for Disease Control and Prevention. What Can Decrease HIV Risk? May 2020. https://hivrisk.cdc.gov/can-decrease-hiv-risk/. (Accessed February 9, 2024).
18. Centers for Disease Control and Prevention. Male (External) Condom Use. February 2022. https://www.cdc.gov/condomeffectiveness/external-condom-use.html. (Accessed February 9, 2024).
19. Centers for Disease Control and Prevention. Female (Internal) Condom Use. November 2021. https://www.cdc.gov/condomeffectiveness/internal-condom-use.html. (Accessed February 9, 2024).
20. Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, Reno H, Zenilman JM, Bolan GA. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep. 2021 Jul 23;70(4):1-187.
21. Centers for Disease Control and Prevention. HIV and Substance Use. April 2021. https://www.cdc.gov/hiv/basics/hiv-transmission/substance-use.html. (Accessed February 9, 2024).
22. Substance Abuse and Mental Health Services Administration. Find Help. https://www.samhsa.gov/find-help. (Accessed February 9, 2024).
23. Centers for Disease Control and Prevention. How Can I Prevent Getting or Transmitting HIV? January 2022. https://hivrisk.cdc.gov/can-prevent-getting-transmitting-hiv/. (Accessed February 9, 2024).
24. United States Department of Labor. Occupational Safety and Health Administration. 29 CFR 1910.1030. Occupational Safety and Health Standards; Bloodborne pathogens. https://www.osha.gov/pls/oshaweb/owadisp.show_document?p_id=10051&p_table=STANDARDS. (Accessed February 9, 2024).
25. Occupational Safety and Health Administration. OSHA fact sheet: OSHA's bloodborne pathogens standard. January 2011. https://www.osha.gov/OshDoc/data_BloodborneFacts/bbfact01.pdf. (Accessed February 9, 2024).
26. US Preventive Services Task Force; Barry MJ, Nicholson WK, Silverstein M, et al. Preexposure Prophylaxis to Prevent Acquisition of HIV: US Preventive Services Task Force Recommendation Statement. JAMA. 2023 Aug 22;330(8):736-745.
27. US Public Health Service. Preexposure Prophylaxis for the Prevention of HIV Infection in the United States – 2021 Update. https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf. (Accessed February 12, 2024).
28. Clinical Pharmacology powered by ClinicalKey. Tampa (FL): Elsevier. 2024. http://www.clinicalkey.com. (Accessed February 12, 2024).
30. Riddell J 4th, Amico KR, Mayer KH. HIV preexposure prophylaxis: a review. JAMA. 2018;319:1261-8.
31. Silapaswan A, Krakower D, Mayer KH. Pre-exposure prophylaxis: a narrative review of provider behavior and interventions to increase PrEP implementation in primary care. J Gen Intern Med. 2017;32:192-8.
32. US Food and Drug Administration. FDA briefing document. Meeting of the Antimicrobial Drugs Advisory Committee. August 2019. https://www.fda.gov/media/129607/download. (Accessed February 12, 2024).
33. Tan DHS, Hull MW, Yoong D, et al. Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis. CMAJ. 2017;189:E1448-58.
34. Molina JM, Capitant C, Spire B, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med 2015;373:2237-46.
35. Centers for Disease Control and Prevention. Updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV – United States, 2016. https://www.cdc.gov/hiv/pdf/programresources/cdc-hiv-npep-guidelines.pdf. (Accessed February 12, 2024).
36. Hughes C, Yoong D, Giguere P, et al. Canadian guideline on HIV preexposure prophylaxis and nonoccupational postexposure prophylaxis for pharmacists. Can J Pharm (Ott). 2019;152:81-91.
37. Kuhar DT, Henderson DK, Struble KA, et al. Updated U.S. Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. Infect Control Hosp Epidemiol. 2013;34:875-92.
38. Johns Hopkins University HIV Clinical Guidelines Program. PEP to Prevent HIV Infection. April 2023. https://www.hivguidelines.org/guideline/hiv-pep/?mycollection=pep-prep. (Accessed February 12, 2024).
39. Centers for Disease Control and Prevention. Post-Exposure Prophylaxis (PEP). August 2022. https://www.cdc.gov/hiv/risk/pep/index.html. (Accessed February 12, 2024).
40. University of California, San Francisco. National Clinician Consultation Center. PEP: Post-Exposure Prophylaxis. https://nccc.ucsf.edu/clinician-consultation/pep-post-exposure-prophylaxis/. (Accessed February 12, 2024).
41. University of Liverpool. HIV Drug Interactions. https://www.hiv-druginteractions.org/checker. (Accessed February 12, 2024).
42. US Department of Health and Human Services. HIV Overview: The Stages of HIV Infection. August 2021. https://hivinfo.nih.gov/understanding-hiv/fact-sheets/stages-hiv-infection. (Accessed February 12, 2024).
43. US Department of Health and Human Services. ClinicalInfo on HIV.gov. HIV/AIDS Glossary: AIDS-Defining Condition. https://clinicalinfo.hiv.gov/en/glossary/aids-defining-condition. (Accessed February 14, 2024).
44. US Department of Health and Human Services. HIV and Opportunistic Infections, Coinfections, and Conditions: What is an Opportunistic Infection? August 2021. https://hivinfo.nih.gov/understanding-hiv/fact-sheets/what-opportunistic-infection. (Accessed February 12, 2024).
45. US Department of Veterans Affairs. HIV: AIDS-defining illnesses. https://www.hiv.va.gov/patient/diagnosis/OI-AIDS-defining-illnesses.asp. (Accessed February 12, 2024).
46. Department of Veterans Affairs. Preventing Opportunistic Infections (OIs). https://www.hiv.va.gov/HIV/mobile/index.asp?page=/patient/diagnosis/OI-prevention&m=y. (Accessed February 12, 2024).
47. US Department of Health and Human Services. HIV Treatment: HIV and Immunizations. December 2023. https://hivinfo.nih.gov/understanding-hiv/fact-sheets/hiv-and-immunizations. (Accessed February 12, 2024).
48. Centers for Disease Control and Prevention. Immunization Schedules For Healthcare Providers. https://www.cdc.gov/vaccines/schedules/hcp/index.html. (Accessed February 12, 2024).
49. US Department of Health and Human Services. COVID-19 and People with HIV. January 2024. https://www.hiv.gov/hiv-basics/staying-in-hiv-care/other-related-health-issues/coronavirus-covid-19. (Accessed February 12, 2024).
50. Centers for Disease Control and Prevention. Traveling with HIV. May 2021. https://www.cdc.gov/hiv/basics/livingwithhiv/travel.html. (Accessed February 12, 2024).
51. US Department of Health and Human Services. ClinicalInfo on HIV.gov. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. September 2023. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-oi/guidelines-adult-adolescent-oi.pdf. (Accessed February 12, 2024).
52. US Department of Health and Human Services. ClinicalInfo on HIV.gov. Clinical Guidelines. https://clinicalinfo.hiv.gov/en/guidelines. (Accessed February 12, 2024).
53. US Department of Health and Human Services. ClinicalInfo on HIV.gov. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. December 2023. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf. (Accessed February 12, 2024).
54. Highleyman L. Switching to TAF-based PrEP improves kidney and bone markers – but does it raise cardiovascular risk? October 2019. https://www.aidsmap.com/news/oct-2019/switching-taf-based-prep-improves-kidney-and-bone-markers-does-it-raise. (Accessed February 12, 2024).
55. Joshi M, Clark B, Lee TA. Fanconi Syndrome in Patients With Human Immunodeficiency Virus Treated With Tenofovir-Based Antiretroviral Therapy: A Systematic Literature Review. Ann Pharmacother. 2023 Nov 6:10600280231206703.
56. Clinical Resource, Cytochrome P450 Drug Interactions. Pharmacist's Letter/Prescriber's Letter. June 2020. [360628].
57. Johns Hopkins University HIV Clinical Guidelines Program. Resource: ART Drug-Drug Interactions. April 2023. https://www.hivguidelines.org/guideline/hiv-art-drug-interactions/. (Accessed February 14, 2024).
58. US Department of Health and Human Services. ClinicalInfo on HIV.gov. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV – Drug-Drug Interactions. May 2023. https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/overview?view=full. (Accessed February 14, 2024).
59. US Department of Health and Human Services. ClinicalInfo on HIV.gov. Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States. January 2024. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/perinatal-hiv/guidelines-perinatal.pdf. (Accessed February 14, 2024).
60. University of California, San Francisco. National Clinician Consultation Center. Perinatal HIV/AIDS. https://nccc.ucsf.edu/clinician-consultation/perinatal-hiv-aids/. (Accessed February 12, 2024).
61. US Department of Health and Human Services. ClinicalInfo on HIV.gov. Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States. Appendix B: Safety and Toxicity of Individual Antiretroviral Agents in Pregnancy – Antiretroviral Pregnancy Registry. March 2014. https://clinicalinfo.hiv.gov/en/guidelines/perinatal/safety-toxicity-arv-agents-pregnancy-registry?view=full. (Accessed February 14, 2024).
62. The Florida Legislature. The 2023 Florida statutes. Chapter 381.31: Testing of pregnant women; duty of the attendant. http://www.leg.state.fl.us/Statutes/index.cfm?App_mode=Display_Statute&Search_String=&URL=0300-0399/0384/Sections/0384.31.html. (Accessed February 14, 2024).
63. Feinstein MJ, Hsue PY, Benjamin LA, et al. Characteristics, prevention, and management of cardiovascular disease in people living with HIV: a scientific statement from the American Heart Association. Circulation. 2019;140:e98-e124.
64. Alonso A, Barnes E, Guest JL, et al. HIV infection and incidence of cardiovascular diseases: an analysis of a large healthcare database.J Am Heart Assoc. 2019;8:e012241.
65. Li EH, Foisy MM. Antiretroviral and medication errors in hospitalized HIV-positive patients. Ann Pharmacother. 2014;48:998-1010.
66. POZ. HIV Drug Assistance Programs. February 2023. https://www.poz.com/basics/hiv-basics/drug-assistance-programs. (Accessed February 14, 2024).
67. Health Resources & Services Administration. Ryan White HIV/AIDS Program Legislation. February 2022. https://ryanwhite.hrsa.gov/about/legislation. (Accessed February 14, 2024).
68. Centers for Disease Control and Prevention. HIV Stigma and Discrimination. June 2021. https://www.cdc.gov/hiv/basics/hiv-stigma/index.html. (Accessed February 14, 2024).
Mention of commercial products does not indicate endorsement.